Pakistan-based pharmaceutical giant GlaxoSmithKline Pakistan Limited reported an impressive 23% year-on-year increase in net profit for the first quarter ending March 2026, highlighting robust operational performance and improved cost efficiency.
The company’s net earnings rose to Rs2.61 billion, up from Rs2.13 billion in the same period last year, while earnings per share climbed to Rs8.20 from Rs6.68.
This growth was largely driven by stronger revenues and controlled production costs. Net sales increased by 9% to Rs17.03 billion, whereas the cost of sales grew at a slower pace of 4%, allowing gross profit to jump 20% to Rs6.38 billion.
Despite a rise in operating expenses—including higher spending on marketing, distribution, and administration—the company maintained solid profitability. Operating profit expanded by 19% to Rs4.31 billion, supported by improved margins.
A major boost came from a sharp decline in financial charges, which dropped by around 80% to just Rs23 million. This reduction significantly strengthened profit before tax, which increased by over 20% to Rs4.29 billion.
Even after a higher tax burden of Rs1.68 billion, the company successfully delivered strong bottom-line growth, underscoring its resilience and operational discipline in a challenging economic environment.
Overall, the results reflect a combination of steady revenue expansion, effective cost management, and reduced debt-related expenses—positioning GLAXO as a strong performer in Pakistan’s pharmaceutical sector.